Clinical Trial Trends: Decentralized Trials, Digital Biomarkers & RWE to Speed Inclusive Research
Clinical Trial Insights: Practical Trends Shaping Faster, More Inclusive Research
Clinical trials are evolving rapidly as sponsors, sites, and regulators pursue faster answers with better patient experience and more reliable data. Several converging trends are reshaping how studies are designed and run—understanding them helps teams reduce timelines, increase retention, and generate evidence that translates to real-world use.
Why change is happening
Patient expectations, advances in digital health, and a growing emphasis on representative data are driving a shift away from clinic-centric models. Regulators and payers are increasingly receptive to evidence generated outside traditional settings, creating room for innovation in trial design and data sources.
Key trends and implications
– Decentralized clinical trials (DCTs)
DCT elements—telemedicine visits, home nursing, remote consent, and local lab partnerships—lower geographic barriers and improve retention. Implement DCT components where protocol risk and endpoint measurement allow, and plan for hybrid approaches that blend site-based and remote activities to maintain data quality while improving access.
– Digital biomarkers and wearables
Continuous monitoring via wearables and smartphone apps provides objective, high-frequency data on mobility, sleep, heart rate variability, and more.
Prioritize device validation for the intended endpoint, ensure participant training and support, and implement robust algorithms to filter noise and artifacts.
– Real-world evidence (RWE)
RWE from electronic health records, registries, and claims can supplement randomized data for external control arms, long-term safety, and effectiveness assessments.
Address data provenance, completeness, and confounding through careful study design and prespecified analysis plans. Early engagement with regulators about RWE use cases mitigates downstream risk.
– Diversity, equity, and inclusion (DEI)
Trials that reflect the patient population improve generalizability and reduce post-approval uncertainties. Use targeted outreach, community partnerships, and flexible visit options to reach underrepresented groups. Incorporate patient advisory boards to identify barriers and tailor consent materials and trial schedules.
– Adaptive and platform trial designs
Adaptive designs, master protocols, and platform trials increase efficiency by using shared infrastructure and allowing multiple hypotheses to be tested within one framework. Emphasize clear decision rules, simulation-based planning, and statistical rigor to maintain credibility with stakeholders.
– Data interoperability and privacy
Interoperability standards and common data models facilitate aggregation of multi-source data. Invest in secure, privacy-preserving architectures, and be transparent about data use to build participant trust. Robust audit trails and reproducible pipelines support regulatory submissions.
Operational recommendations for sponsors and CROs
– Start patient engagement early: Conduct usability testing for digital tools, iterate informed consent materials, and set expectations about participation burden.
– Build hybrid protocols: Identify which procedures must remain site-based and which can move remote; pilot hybrid elements in a smaller cohort before full rollout.
– Validate endpoints and devices: Use analytical and clinical validation to ensure digital measures map to meaningful outcomes.
– Plan for data flow complexity: Map data sources, latency, and governance upfront; allocate resources for data harmonization and cleaning.
– Engage regulators and payers early: Discuss novel endpoints, RWE plans, and adaptive features to reduce surprises during review.
Measuring success
Beyond traditional recruitment and retention metrics, track participant satisfaction, data completeness from remote sources, time to database lock, and representativeness of enrolled populations. Continuous learning loops—post-study debriefs and patient feedback—drive iterative improvement.
Actionable first step
Audit your upcoming protocols for patient burden, digital opportunity, and diversity gaps. A rapid feasibility review can identify quick wins—such as adding remote visits or partnering with local labs—that materially improve enrollment and retention without overhauling the entire design.